Healthcare
Vir Biotechnology, Inc.(VIR)
Live Price
Offline$8.61
+1.06% today
1Y Change
+70.50%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $1.61B
- Revenue Growth
- -7.6%
- EPS Growth
- +17.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vir Biotechnology, Inc. (VIR) is a Healthcare stock with a market cap of $1.61B and listed on NASDAQ. The stock last traded around $8.61 and up 70.5% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -7.6%, EPS growth of +17.5%, a dividend yield of 0.0%. What stands out right now is revenue -7.6%, EPS +17.5%, free cash flow +12.6% with operating margin -682.7% and ROIC -50.9%. Valuation already assumes a fairly strong business story at price/sales 23.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VIR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-7.6% vs +7.6% peer median
Operating Margin
Below sector median
-682.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -7.6% and EPS is at +17.5%, with operating margin around -682.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -9.9% | -9.3% | -11.1% |
2026 Feb 23, 2026 | +26.2% | +27.7% | +25.7% | +19.0% |
2025 Nov 5, 2025 | -67.1% | -5.2% | +5.7% | +25.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VIR
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VIR Max Drawdown
-27.82%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VIR and SPY.
Company Overview
Vir Biotechnology, Inc.
NASDAQ Global Select
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
- Leadership
- Marianne De Backer
- IPO Date
- Oct 11, 2019
- Employees
- 408
- Street Address
- 499 Illinois Street
- Mailing
- San Francisco, CA, 94158
- Region
- San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 415 906 4324
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 23.5
- Price/Book
- 1.8
Growth
- Revenue
- -7.6%
- EPS
- +17.5%
- Free Cash Flow
- +12.6%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -682.7%
- Net Margin
- -638.9%
- ROE
- -49.3%
- ROIC
- -50.9%
Balance Sheet
- Debt/Equity
- 0.24
- Current Ratio
- 5.54
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.